Pharma / Biotech

Adding Dexmedetomidine for AWS Misses the Mark

Use of dexmedetomidine as a safer alternative to benzodiazepine for the treatment of alcohol withdrawal syndrome failed to reduce adverse events and hospital stays, according to two recent studies.

Source link

Related posts

FDA Approves Hadlima Biosimilar for RA, Other Inflammatory Condition


CEFOXITIN (Cefoxitin Sodium) Powder, For Solution [Fresenius Kabi USA, LLC]


TARTAR CONTROL PLUS (eucalyptol, menthol, methyl salicylate, thymol) mouthwash [Publix Super Markets]


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World